NCT07530094 2026-04-15
STELLAR01
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
Clinical Trials
84 trialsNCT03485209 2026-04-07
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT03764553 2026-04-07
LyRICX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT06535607 2026-03-24
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT07490002 2026-03-24
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
Changhai Hospital
Phase 2 Not yet recruiting
NCT06493019 2026-03-23
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02297217 2025-12-16
PaRCUS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07266493 2025-12-05
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT04175912 2025-11-17
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06965829 2025-05-11
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06599775 2024-09-19
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06084897 2024-06-14
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05807542 2024-05-16
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT06403878 2024-05-08
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Sichuan University
Phase 2 Recruiting
NCT02931890 2024-05-02
CRITICS-II
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed
NCT02287129 2023-11-28
MEMORI
Technical University of Munich
Phase 2 Completed
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT05302011 2023-10-10
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06056336 2023-09-28
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT00003864 2023-06-15
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05896787 2023-06-09
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT01333033 2023-04-13
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed